![Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1 | Business Wire Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1 | Business Wire](https://mms.businesswire.com/media/20211118006392/en/1106824/23/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg)
Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1 | Business Wire
![Design of single and multiple once-weekly rising-dose trial of MK-8507... | Download Scientific Diagram Design of single and multiple once-weekly rising-dose trial of MK-8507... | Download Scientific Diagram](https://www.researchgate.net/publication/354565004/figure/tbl2/AS:1108577276182534@1641316827790/Design-of-single-and-multiple-once-weekly-rising-dose-trial-of-MK-8507-with-midazolam.png)
Design of single and multiple once-weekly rising-dose trial of MK-8507... | Download Scientific Diagram
![Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg | HTB | HIV i-Base Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg | HTB | HIV i-Base](https://i-base.info/htb/wp-content/uploads/2020/10/glasgow-logo-3-291x300.png)
Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg | HTB | HIV i-Base
![MK-8507 plasma PK following administration of single oral MK-8507 doses... | Download Scientific Diagram MK-8507 plasma PK following administration of single oral MK-8507 doses... | Download Scientific Diagram](https://www.researchgate.net/publication/354565004/figure/fig1/AS:1108577276174336@1641316827728/MK-8507-plasma-PK-following-administration-of-single-oral-MK-8507-doses-in-adults-without.png)
MK-8507 plasma PK following administration of single oral MK-8507 doses... | Download Scientific Diagram
![Synthesis and characterization of a novel 18 F-labeled 2,5-diarylnicotinamide derivative targeting orexin 2 receptor - MedChemComm (RSC Publishing) DOI:10.1039/C9MD00397E Synthesis and characterization of a novel 18 F-labeled 2,5-diarylnicotinamide derivative targeting orexin 2 receptor - MedChemComm (RSC Publishing) DOI:10.1039/C9MD00397E](https://pubs.rsc.org/image/article/2019/MD/c9md00397e/c9md00397e-f1_hi-res.gif)